FRONTIER BIOTECHNOLOGIES Inc.

Frontier Biotechnologies Inc.

Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health.  Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval.  Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, our long-standing commitment to excellence is in everything we do through the entire development cycle from drug discovery, preclinical research to global clinical development.  This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.

Frontier Biotechnologies Inc.(Nanjing)

Nanjing: company headquarter, GMP manufacturing facility for peptide API and finished productsChongqing: R&D and marketingBeijing: Center for clinical research, regulatory, government affairs, mar

Products

Long-Acting Peptide Drug

Frontier Biotech has established an extraordinarilytalented R&D teamwith deep expertise and extensive experience in all aspects of new drug development. Successful development and launch of Aikening ® have enabled Frontier Biotech to develop a state-of-the-art platform for the advancement of long-acting peptide drug innovation, which in turn lays a solid foundation for expandingour product portfolio and further strengtheningFrontier's global competence.

Partnering

Develop Innovative Therapies to Better Human Lives